Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  DeGraff, David J ^a   Clark, Peter E ^a   Cates, Justin M ^a   Yamashita, Hironobu ^a   Robinson, Victoria L ^b   Yu, Xiuping ^a   Smolkin, Mark E ^c   Chang, Sam S ^a   Cookson, Michael S ^a   Herrick, Mary K ^a   Shariat, Shahrokh F ^d   Steinberg, Gary D ^b   Frierson, Henry F ^e   Wu, Xue Ru ^f   Theodorescu, Dan ^g   Matusik, Robert J ^a,h  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; UNCLASSIFIED DRUG; UROPLAKIN 1B; UROPLAKIN 2; UROPLAKIN 3; UROPLAKIN 3A; UROPLAKIN 3B; UVOMORULIN; CADHERIN; DIFFERENTIATION ANTIGEN; FOXA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CELL; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CELL SUBPOPULATION; DISEASE ASSOCIATION; ENGRAFTMENT; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ENGINEERING; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KERATINIZING SQUAMOUS CELL METAPLASIA; KIDNEY CAPSULE; KIDNEY INTERSTITIUM; LOGISTIC REGRESSION ANALYSIS; MALE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL METAPLASIA; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; UROTHELIUM; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; CANCER TRANSPLANTATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MOUSE; MOUSE MUTANT; PATHOLOGY; RAT;

RATTUS;

ANIMALS; ANTIGENS, DIFFERENTIATION; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; RATS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84860999189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036669     Document Type: Article

References (66)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians 61: 212-236.
2. Oottamasathien S, Wang Y, Williams K, Franco OE, Wills ML, et al. (2007) Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol 304: 556-566.
3. Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, et al. (2008) Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol 180: 1784-1789.
4. Mauney JR, Ramachandran A, Yu RN, Daley GQ, Adam RM, et al. (2010) All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One 5: e11513.
5. Varley CL, Bacon EJ, Holder JC, Southgate J, (2009) FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death Differ 16: 103-114.
6. Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, et al. (2004) Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci 117: 2029-2036.
7. Georgopoulos NT, Kirkwood LA, Varley CL, MacLaine NJ, Aziz N, et al. (2011) Immortalisation of normal human urothelial cells compromises differentiation capacity. European urology 60: 141-149.
8. Myatt SS, Lam EW, (2007) The emerging roles of forkhead box (Fox) proteins in cancer. Nature reviews Cancer 7: 847-859.
9. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, et al. (2009) Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proceedings of the National Academy of Sciences of the United States of America 106: 5807-5812.
10. Rigby CC, Franks LM, (1970) A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. British journal of cancer 24: 746-754.
11. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, et al. (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11: 765-773.
12. O'Toole C, Price ZH, Ohnuki Y, Unsgaard B, (1978) Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 38: 64-76.
13. Fogh J, (1978) Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr pp. 5-9.
14. Wilson GN, Dasouki M, Grossman HB, (1987) Cell-specific ribosomal DNA spacer variability in human urothelial carcinoma cultures. The Journal of urology 137: 324-326.
15. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, et al. (1995) Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154: 1532-1538.
16. O'Toole C, Nayak S, Price Z, Gilbert WH, Waisman J, (1976) A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder. International journal of cancer Journal international du cancer 17: 707-714.
17. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, et al. (1980) The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37: 115-132.
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23.
19. Knowles BB, Howe CC, Aden DP, (1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499.
20. Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, et al. (2003) Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. The Journal of pathology 199: 41-49.
21. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ, (2011) Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30: 1868-1879.
22. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, et al. (2006) Expression and role of Foxa proteins in prostate cancer. The Prostate 66: 1013-1028.
23. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, et al. (2005) Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132: 3431-3443.
24. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, et al. (2007) Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol 38: 1703-1713.
25. DeGraff DJ, Malik M, Chen Q, Miyako K, Rejto L, et al. (2007) Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model. J Cell Physiol 213: 261-268.
26. Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, et al. (1997) Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. The Journal of biological chemistry 272: 5007-5015.
27. Besnard V, Wert SE, Hull WM, Whitsett JA, (2004) Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr Patterns 5: 193-208.
28. McMahon AP, Aronow BJ, Davidson DR, Davies JA, Gaido KW, et al. (2008) GUDMAP: the genitourinary developmental molecular anatomy project. J Am Soc Nephrol 19: 667-671.
29. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT, (2009) Uroplakins in urothelial biology, function, and disease. Kidney Int 75: 1153-1165.
30. Wu XR, Lin JH, Walz T, Haner M, Yu J, et al. (1994) Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. The Journal of biological chemistry 269: 13716-13724.
31. Shokeir AA, (2004) Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU international 93: 216-220.
32. Song Y, Washington MK, Crawford HC, (2010) Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70: 2115-2125.
33. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nature reviews Cancer 5: 713-725.
34. Wu XR, (2009) Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer metastasis reviews 28: 281-290.
35. Retz M, Rotering J, Nawroth R, Buchner A, Stockle M, et al. (2011) Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. European urology 60: 231-238.
36. Klein CA, (2009) Parallel progression of primary tumours and metastases. Nature reviews Cancer 9: 302-312.
37. Augello MA, Hickey TE, Knudsen KE, (2011) FOXA1: master of steroid receptor function in cancer. The EMBO journal 30: 3885-3894.
38. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, et al. (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Molecular endocrinology 17: 1484-1507.
39. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS, (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature genetics 43: 27-33.
40. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, et al. (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer cell 13: 141-152.
41. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, et al. (2011) Impact of gender on bladder cancer incidence, staging, and prognosis. World journal of urology 29: 457-463.
42. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF, (2011) Sex disparities in cancer mortality and survival. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20: 1629-1637.
43. Gierer A, (1974) Molecular models and combinatorial principles in cell differentiation and morphogenesis. Cold Spring Harbor symposia on quantitative biology 38: 951-961.
44. Kwon DN, Choi YJ, Park JY, Cho SK, Kim MO, et al. (2006) Cloning and molecular dissection of the 8.8 kb pig uroplakin II promoter using transgenic mice and RT4 cells. Journal of cellular biochemistry 99: 462-477.
45. Ahmad I, Barnetson RJ, Krishna NS, (2008) Keratinizing squamous metaplasia of the bladder: a review. Urologia internationalis 81: 247-251.
46. Molloy CJ, Laskin JD, (1988) Effect of retinoid deficiency on keratin expression in mouse bladder. Exp Mol Pathol 49: 128-140.
47. Chytil F, (1992) The lungs and vitamin A. The American journal of physiology 262: L517-527.
48. Munday JS, McKinnon H, Aberdein D, Collett MG, Parton K, et al. (2009) Cystitis, pyelonephritis, and urolithiasis in rats accidentally fed a diet deficient in vitamin A. Journal of the American Association for Laboratory Animal Science: JAALAS 48: 790-794.
49. Liang FX, Bosland MC, Huang H, Romih R, Baptiste S, et al. (2005) Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. The Journal of cell biology 171: 835-844.
50. Jacob A, Budhiraja S, Reichel RR, (1999) The HNF-3alpha transcription factor is a primary target for retinoic acid action. Exp Cell Res 250: 1-9.
51. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, et al. (2009) Inactivation of p 53 and Pten promotes invasive bladder cancer. Genes & development 23: 675-680.
52. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, et al. (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 5060-5072.
53. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, et al. (2008) Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 1478-1486.
54. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, et al. (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. The Journal of pathology 215: 184-194.
55. Tanaka ST, Ishii K, Demarco RT, Pope JCt, Brock JW 3rd, et al. (2010) Endodermal origin of bladder trigone inferred from mesenchymal-epithelial interaction. The Journal of urology 183: 386-391.
56. Cunha GR, Lung B, (1979) The importance of stroma in morphogenesis and functional activity of urogenital epithelium. In vitro 15: 50-71.
57. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, et al. (2011) Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer research 71: 1272-1281.
58. Ishii K, Shappell SB, Matusik RJ, Hayward SW, (2005) Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Laboratory investigation; a journal of technical methods and pathology 85: 1086-1103.
59. Hodges GM, Hicks RM, Spacey GD, (1977) Epithelial-stromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer Res 37: 3720-3730.
60. Hicks RM, (1977) Discussion of morphological markers of early neoplastic change in the urinary bladder. Cancer Res 37: 2822-2823.
61. Uchida K, Samma S, Momose H, Kashihara N, Rademaker A, et al. (1990) Stimulation of urinary bladder tumorigenesis by carcinogen-exposed stroma. J Urol 143: 618-621.
62. Hicks RM, (1977) Discussion of morphological markers of early neoplastic change in the urinary bladder. Cancer research 37: 2822-2823.
63. Hodges GM, Hicks RM, Spacey GD, (1977) Epithelial-stromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer research 37: 3720-3730.
64. Uchida K, Samma S, Momose H, Kashihara N, Rademaker A, et al. (1990) Stimulation of urinary bladder tumorigenesis by carcinogen-exposed stroma. The Journal of urology 143: 618-621.
65. Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, et al. (2008) Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res 68: 4709-4718.
66. Li X, Wang Y, Sharif-Afshar AR, Uwamariya C, Yi A, et al. (2009) Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation 77: 95-102.